# VKTX catalysts: Viking Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vktx/catalysts

> Viking Therapeutics, Inc. (VKTX) has 8 upcoming catalysts. The next is the VK2735 primary completion, July 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Viking Therapeutics, Inc. |
| Ticker | VKTX (Nasdaq) |
| SEC CIK | 1607678 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/vktx |

## Cash runway

Cash $959.8M as of 2026-09-30; quarterly burn $138.2M; about 20.8 months of runway at that rate (XBRL company facts, accession 0001193125-26-436432).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2023 | [VK2809 topline data readout](https://sec-api.dev/pdufa/vk2809) | VKTX |  | completed, positive | "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)) |
| Sep 2023 | [VK2735 trial start](https://sec-api.dev/pdufa/vk2735) | VKTX | obesity | completed | "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)) |
| Feb 2024 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX | obesity, in June 2025, we | completed, positive | "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, in June 2025, we announced the initiation of our VANQUISH Phase 3 program for the subcutaneous formulation." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)) |
| January 8, 2025 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX |  | completed, positive | "On January 8, 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and on August 19, 2025, we announced positive top-line results from the trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1607678/000119312525247059/vktx-20250930.htm)) |
| February 5, 2025 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/vktx-ex99_1.htm)) |
| Q2 2025 | [VK2735 trial start](https://sec-api.dev/pdufa/vk2735) | VKTX |  | scheduled | "Based on written feedback received from the U.S. Food and Drug Administration, or the FDA, we expect to initiate Phase 3 clinical studies of the subcutaneous formulation of VK2735 in the second quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1607678/000095017025058129/vktx-20250331.htm)) |
| April 23, 2025 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000095017025057337/vktx-ex99_1.htm)) |
| June 24, 2025 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | completed | "NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06828055)) |
| July 23, 2025 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/vktx-ex99_1.htm)) |
| August 19, 2025 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX |  | completed, positive | "SAN DIEGO, CA - August 19, 2025 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000160767825000003/vktx-ex99_1.htm)) |
| Oct 2025 | [VK2735 trial start](https://sec-api.dev/pdufa/vk2735) | VKTX |  | completed | "In October 2025, Viking initiated a Phase 1 dose-ranging study designed to explore the feasibility of various VK2735 maintenance dosing regimens." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-ex99_1.htm)) |
| October 22, 2025 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312525246775/vktx-ex99_1.htm)) |
| February 11, 2026 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-ex99_1.htm)) |
| Q2 2026 | [VK3019 trial start](https://sec-api.dev/pdufa/vk3019) | VKTX |  | scheduled | "We plan to initiate a Phase 1 Trial evaluating VK3019 in the second quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1607678/000119312526193315/vktx-20260331.htm)) |
| April 29, 2026 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm)) |
| July 29, 2026 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-ex99_1.htm)) |
| September 22, 2026 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX |  | completed, positive | "SAN DIEGO, CA - September 22, 2026 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's maintenance study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-ex99_1.htm)) |
| Q4 2026 | [VK2735 trial start](https://sec-api.dev/pdufa/vk2735) | VKTX |  | scheduled | "-- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm)) |
| October 28, 2026 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436145/vktx-ex99_1.htm)) |
| July 2027 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104383)) |
| Jul to Oct 2027 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104383)) |
| July 2027 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104500 (VK2735 for Weight Management Phase 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104500)) |
| Jul to Oct 2027 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104500 (VK2735 for Weight Management Phase 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104500)) |
| July 2028 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07868835 (Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868835)) |
| Jul to Oct 2028 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07868835 (Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868835)) |
| October 2028 | [Vk2735 oral primary completion](https://sec-api.dev/pdufa/vk2735-oral) | VKTX | Weight Loss | scheduled | "NCT07868939 (Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868939)) |
| Oct 2028 to Jan 2029 | [Vk2735 oral topline data readout](https://sec-api.dev/pdufa/vk2735-oral) | VKTX | Weight Loss | scheduled | "NCT07868939 (Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868939)) |

## Drugs

- [VK2735](https://sec-api.dev/pdufa/vk2735): obesity, obesity, in june 2025, we, obesity, and in june 2025, we, Weight Loss
- [Vk2735 oral](https://sec-api.dev/pdufa/vk2735-oral): Weight Loss
- [VK2809](https://sec-api.dev/pdufa/vk2809): 
- [VK3019](https://sec-api.dev/pdufa/vk3019): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vktx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VKTX catalysts: Viking Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vktx/catalysts

```bibtex
@misc{secapidev_companies_vktx_catalysts_20261116,
  title        = {VKTX catalysts: Viking Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vktx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vktx_catalysts_20261116","title":"VKTX catalysts: Viking Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vktx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
